• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


OSB Lead-INTERMACS Companion

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Application Number P030011 S011/ PAS002
Current Plan Approved 11/27/2015
Study Name OSB Lead-INTERMACS Companion
General Study Protocol Parameters
Study Design Prospective & Retrospective Study
Data Source External Registry
Comparison Group Concurrent & Historical Control
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description This is a two쳌]armed (partially retrospective and partially prospective), multi쳌]center, non쳌] randomized, cohort registry study that uses the INTERMACS Registry to compare performance of the TAH쳌]t when supported with the Companion 2 Driver System vs. performance of the TAH쳌] t when supported with the CSS Console.
Study Population Description Patients in the INTERMACS Registry who are implanted with the

TAH쳌]t and used the C2 Driver System as their initial driver.

There will be 2 control groups used for comparison. One consists of

all Patients in the INTERMACS Registry who are implanted with the TAH쳌]t who used the CSS Console. The other consists only patients in the INTERMACS Registry who were implanted with the TAH쳌]t after The C2 Driver System began to be used (June 2012).

Sample Size The study will be composed of 200 patients supported by the Companion 2 Driver System and all INTERMACS Registry patients supported by the CSS Console at the time that the sample size for the C2 Driver System reaches 200.
Data Collection The primary endpoint is survival rate, defined as noted above for the study hypotheses.
Follow-up Visits and Length of Follow-up 4 years

Per INTERMACS Registry (1 week, 1 month, 3 month, 6 month and every 6 months thereafter).

OSB Lead-INTERMACS Companion Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
six month report 06/24/2014 06/24/2014 On Time
one year report 02/11/2015 02/18/2015 Overdue/Received
18 month report 06/24/2015 06/24/2015 On Time
two year report 01/25/2016 01/27/2016 Overdue/Received
three year report 12/24/2016    
four year report 12/24/2017    

Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Related Links